Press release
Investigation announced for Long-Term Investors in shares of NextCure, Inc. (NASDAQ: NXTC)
An investigation on behalf of current long term investors in NextCure, Inc. (NASDAQ: NXTC) shares.
Investors who are current long term investors in NextCure, Inc. (NASDAQ: NXTC) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in NASDAQ: NXTC stocks follows a lawsuit filed against NextCure, Inc. over alleged securities laws violations. The investigation on behalf of current long term investors in NASDAQ: NXTC stocks, concerns whether certain NextCure directors are liable in connection with the allegations made in that lawsuit.
According to that complaint filed in the U.S. District Court for the Southern District of New York the plaintiff alleges that the defendants violated provisions of the Exchange and Securities Acts by misleading investors regarding its leading treatment candidate, NC318. Specifically, the complaint alleges that statements made by Defendants concerning the effectiveness of NC318, the responses observed in patients treated with NC318, and NC318’s potential to treat patients’ refractory to PD-1 therapies were false and misleading.
Those who purchased shares of NextCure, Inc. (NASDAQ: NXTC) have certain options and should contact the Shareholders Foundation.
Media Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Investigation announced for Long-Term Investors in shares of NextCure, Inc. (NASDAQ: NXTC) here
News-ID: 2224869 • Views: …
More Releases from Shareholders Foundation
Lawsuit for Investors in Sonder Holdings Inc. (NASDAQ: SOND) filed in effort to …
An investor, who purchased shares of Sonder Holdings Inc. (NASDAQ: SOND), filed a lawsuit over alleged violations of Federal Securities Laws by Sonder Holdings Inc in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Sonder Holdings Inc. (NASDAQ: SOND) have certain options and for certain investors are short and strict deadlines running. Deadline: June 10, 2024. NASDAQ: SOND investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com…
Lawsuit filed for Investors in Ocugen, Inc. (NASDAQ: OCGN) in effort to recover …
An investor, who purchased shares of Ocugen, Inc. (NASDAQ: OCGN), filed a lawsuit i over alleged violations of Federal Securities Laws by Ocugen, Inc..
Investors who purchased shares of Ocugen, Inc. (NASDAQ: OCGN) have certain options and for certain investors are short and strict deadlines running. Deadline: June 10, 2024. NASDAQ: OCGN investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
Malvern, PA based Ocugen, Inc., a…
Investors who lost money with shares of Evolv Technologies Holdings, Inc. (NASDA …
An investor, who purchased shares of Evolv Technologies Holdings, Inc. (NASDAQ: EVLV), filed a lawsuit in the U.S. District Court for the District of Massachusetts over alleged violations of Federal Securities Laws by Evolv Technologies Holdings, Inc. f/k/a NewHold Investment Corp.
Investors who purchased shares of Evolv Technologies Holdings, Inc. (NASDAQ: EVLV) have certain options and for certain investors are short and strict deadlines running. Deadline: May 24, 2024. NASDAQ: EVLV…
Investigation announced for Investors who purchased shares of Comtech Telecommun …
Comtech Telecommunications Corp is under investigation over potential securities laws violations in connection with certain financial statements.
Investors who purchased shares of Comtech Telecommunications Corp. (NASDAQ: CMTL), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm focuses on whether a series of statements by Comtech Telecommunications Corp. regarding its business, its prospects and its operations were materially false…
More Releases for NextCure
Tumor Immunotherapy Market 2022: Covid-19 Impact, Competitive Landscape, Growth …
Global Tumor Immunotherapy Market Research Report provides a key analysis of the market status of the Tumor Immunotherapy with the best facts and figures, meaning, definition, SWOT analysis, expert opinions, and the latest developments across the globe. The report also calculates the market size, Sales, Price, Revenue, Gross Margin, Market Share, cost structure, and growth rate. The report considers the revenue generated from the sales of this Report and technologies…
Investigation announced for Long-Term Investors in NextCure, Inc. (NASDAQ: NXTC)
An investigation on behalf of current long-term investors in shares of NextCure, Inc. (NASDAQ: NXTC) concerning potential breaches of fiduciary duties by certain directors and officers of NextCure, Inc. (NASDAQ: NXTC was announced.
Investors who are current long term investors in NextCure, Inc. (NASDAQ: NXTC) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current…
Deadline on Nov. 20th coming up in Lawsuit filed for Investors in NextCure, Inc. …
A deadline is coming up on November 20, 2020 in the lawsuit filed for certain investors of NextCure, Inc. (NASDAQ: NXTC).
Investors who purchased shares of NextCure, Inc. (NASDAQ: NXTC) have certain options and there are strict and short deadlines running. Deadline: November 20, 2020. NASDAQ: NXTC stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
According to the complaint filed in the U.S. District Court for…
Lawsuit filed for Investors in shares of NextCure, Inc. (NASDAQ: NXTC)
An investor, who purchased shares of NextCure, Inc. (NASDAQ: NXTC), filed a lawsuit over alleged violations of Federal Securities Laws by NextCure, Inc., certain directors and officers of the Company, and the underwriters of NextCure’s November 2019 public offering.
Investors who purchased shares of NextCure, Inc. (NASDAQ: NXTC) have certain options and for certain investors are short and strict deadlines running. Deadline: November 20, 2020. NASDAQ: NXTC investors should contact…
Clinical Trials Market Study Offers In-depth Competitive Landscape Assessment 20 …
Collaboration at Its Peak: Key Strategy of Manufacturers in Clinical Trials Market
For reducing economic burden, many companies are planning to shift their focus towards on-core business activities, thereby outsourcing their clinical trials activities to the CROs (contract research organizations). This in turn influences biotechnology and pharmaceutical companies for outsourcing clinical trials activities to the CROs in APAC. Major CROs are approached by the drug companies at a notable rate for…
Clinical Trials Market: 2018-2028: Dynamics, Forecast, Analysis and Supply Deman …
Collaboration at Its Peak: Key Strategy of Manufacturers in Clinical Trials Market
For reducing economic burden, many companies are planning to shift their focus towards on-core business activities, thereby outsourcing their clinical trials activities to the CROs (contract research organizations). This in turn influences biotechnology and pharmaceutical companies for outsourcing clinical trials activities to the CROs in APAC. Major CROs are approached by the drug companies at a notable rate for…
